Medicofarma Biotech (WAR:MDB) Cyclically Adjusted FCF per Share: zł-0.05 (As of Mar. 2026)


WAR:MDB Medicofarma Biotech SA WAR:MDB
34 GF Score
Price zł0.42
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech Cyclically Adjusted FCF per Share?

Medicofarma Biotech WAR:MDB +2.44% 34 Cyclically Adjusted FCF per Share is zł-0.05 as of Mar. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 34/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Medicofarma Biotech's adjusted free cash flow per share for the three months ended in Mar. 2026 was zł-0.003. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is zł-0.05 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-12), Medicofarma Biotech's current stock price is zł0.42. Medicofarma Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was zł-0.05. Medicofarma Biotech's Cyclically Adjusted Price-to-FCF of today is .


Medicofarma Biotech  (WAR:MDB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Medicofarma Biotech Cyclically Adjusted FCF per Share Related Terms


Medicofarma Biotech Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Medicofarma Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicofarma Biotech Cyclically Adjusted FCF per Share Chart

Medicofarma Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.05 -0.05 -0.05 -0.05

Medicofarma Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.05 -0.05 -0.05 -0.05

WAR:MDB vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicofarma Biotech Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Medicofarma Biotech's Cyclically Adjusted Price-to-FCF falls into.


WAR:MDB
34GF Score
Medicofarma Biotech SA WAR:MDB
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicofarma Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medicofarma Biotech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.003/163.0700*163.0700
=-0.003

Current CPI (Mar. 2026) = 163.0700.

Medicofarma Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.005 99.552 -0.008
201609 0.009 99.064 0.015
201612 0.014 100.366 0.023
201703 -0.026 101.018 -0.042
201706 0.001 101.180 0.002
201709 -0.005 101.343 -0.008
201712 0.039 102.564 0.062
201803 -0.015 102.564 -0.024
201806 -0.007 103.378 -0.011
201809 -0.008 103.378 -0.013
201812 0.027 103.785 0.042
201903 -0.029 104.274 -0.045
201906 -0.005 105.983 -0.008
201909 -0.024 105.983 -0.037
201912 0.002 107.123 0.003
202003 -0.032 109.076 -0.048
202006 -0.032 109.402 -0.048
202009 -0.003 109.320 -0.004
202012 -0.014 109.565 -0.021
202103 0.000 112.658 0.000
202106 -0.216 113.960 -0.309
202109 0.001 115.588 0.001
202112 0.015 119.088 0.021
202203 -0.001 125.031 -0.001
202206 -0.007 131.705 -0.009
202209 0.011 135.531 0.013
202212 -0.006 139.113 -0.007
202303 -0.016 145.950 -0.018
202306 0.001 147.009 0.001
202309 -0.001 146.113 -0.001
202312 0.001 147.741 0.001
202403 0.004 149.044 0.004
202406 -0.006 150.997 -0.006
202409 -0.006 153.439 -0.006
202412 -0.008 154.660 -0.008
202503 -0.004 157.021 -0.004
202506 -0.005 157.509 -0.005
202509 -0.002 158.000 -0.002
202512 -0.003 158.320 -0.003
202603 -0.003 163.070 -0.003

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of zł-0.05 mean?
Medicofarma Biotech (WAR:MDB) has a Cyclically Adjusted FCF per Share of zł-0.05 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medicofarma Biotech and its competitors.
Is Medicofarma Biotech's Cyclically Adjusted FCF per Share too high?
Medicofarma Biotech's current Cyclically Adjusted FCF per Share is zł-0.05. Overall, Medicofarma Biotech has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Medicofarma Biotech's Cyclically Adjusted FCF per Share of zł-0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medicofarma Biotech and its competitors. Medicofarma Biotech's current Cyclically Adjusted FCF per Share is zł-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.42 — trading 740% above its estimated fair value. The current Cyclically Adjusted FCF per Share is zł-0.05. Medicofarma Biotech's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Cyclically Adjusted FCF per Share is zł-0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.42 is trading 740% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Cyclically Adjusted FCF per Share: zł-0.05
  • GF Value™: zł0.05 vs. price of zł0.42 (740% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
34GF Score

Get the complete analysis for WAR:MDB

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.42
Price
zł0.05
GF Value